Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Clinical trial NCT05232071 · COMPLETED
Trial details
- NCT number
- NCT05232071
- Sponsor
- Inventiva Pharma
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-29
- Primary completion
- 2024-03-30
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.